Support By : Li-lab
PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
---|---|---|---|---|---|
Olfactory transduction | R-HSA-9751605 | map04740 | corbadrine | 2446 | drug-path |
Allograft rejection | R-HSA-9679028 | map05330 | corbadrine | 2446 | drug-path |
Colorectal cancer | R-HSA-4791275 | map05210 | corbadrine | 2446 | drug-path |
Type I diabetes mellitus | R-HSA-5683209 | map04940 | corbadrine | 2446 | drug-path |
Basal cell carcinoma | R-HSA-5626181 | map05217 | corbadrine | 2446 | drug-path |
Graft-versus-host disease | R-HSA-1643685 | map05332 | butyl hydroxybenzoate | 5336 | drug-path |
Hematopoietic cell lineage | R-HSA-173752 | map04640 | butyl hydroxybenzoate | 5336 | drug-path |
Autoimmune thyroid disease | R-HSA-1643685 | map05320 | butyl hydroxybenzoate | 5336 | drug-path |
Shigellosis | 0 | map05131 | butyl hydroxybenzoate | 5336 | drug-path |
Pathogenic Escherichia coli infection | R-HSA-9609646 | map05130 | butyl hydroxybenzoate | 5336 | drug-path |
Asthma | R-HSA-444620 | map05310 | butyl hydroxybenzoate | 5336 | drug-path |
Allograft rejection | R-HSA-9679028 | map05330 | butyl hydroxybenzoate | 5336 | drug-path |
Type I diabetes mellitus | R-HSA-5683209 | map04940 | butyl hydroxybenzoate | 5336 | drug-path |
Systemic lupus erythematosus | R-HSA-977105 | map05322 | butyl hydroxybenzoate | 5336 | drug-path |
Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | butyl hydroxybenzoate | 5336 | drug-path |
Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | indapamide | 3702 | drug-path |
Pathways in cancer | R-HSA-9824443 | map05200 | indapamide | 3702 | drug-path |
Huntington's disease | R-HSA-1643685 | 0 | indapamide | 3702 | drug-path |
Olfactory transduction | R-HSA-9751605 | map04740 | indapamide | 3702 | drug-path |
Cell adhesion molecules (CAMs) | R-HSA-1031690 | 0 | indapamide | 3702 | drug-path |